ABSTRACT Enterovirus‐D68 (EV‐D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV‐D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV‐D68 positive. WIN‐like compounds (pleconaril, pocapavir, and vapendavir) bind to the virus capsid and have been tested against various enteroviruses (EVs) in clinical trials. However, these compounds encountered issues with resistance and adverse effects, which impeded their approval by the Food and Drug Administration (FDA). Presently, the medical field lacks FDA‐approved antiviral treatments or vaccines for EV‐D68. Ongoing research efforts are dedicated to identifying viable therapeutics to address EV‐D68 infections. This review explores the current advancements in antiviral therapies and potential therapeutics to mitigate the significant impact of EV‐D68 infection control.